TLDR:
- US venture capital firms have pulled out of Injective (INJ) and Near Protocol (NEAR).
- Algotech raised $10.3 million, offering hope in the blockchain ecosystem.
Recently, US venture capital firms have abandoned their investments in Injective (INJ) and Near Protocol (NEAR), leading to a dip in cryptocurrency prices. Injective is revolutionizing DeFi with advanced blockchain solutions, offering powerful core financial infrastructure primitives and cross-chain bridging capabilities. NEAR Protocol aims to enhance blockchain with superior performance and interoperability, catering to DApps and providing unique solutions to scaling issues. Despite the market shifts, Algotech stands out, raising $10.3 million in its presale. Algotech is pioneering algorithmic trading, offering a decentralized platform for traders to automate decisions and execute trades based on predefined rules, enhancing transparency and accessibility in the trading world.
